Send the following on WhatsApp
Continue to ChatU.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML https://www.businessline.global/u-s-fda-approves-supplemental-new-drug-application-for-takedas-iclusig-ponatinib-for-adult-patients-with-resistant-or-intolerant-chronic-phase-cml/press-release/